This document provides an outline and summary of a seminar presentation on approaching patients with anemia. It discusses the definition and classification of anemia and covers several common types of anemia - iron deficiency anemia, anemia of chronic disease, megaloblastic anemias, sickle cell anemia, and thalassemia. For each type of anemia, the document outlines etiologies, symptoms, diagnostic criteria, bone marrow findings, and treatment approaches.
Basic approach to a case of anemia. Investigations to do and to arrive at the diagnosis. (Management not discussed). Peripheral smear findings with pictures are included.
Basic approach to a case of anemia. Investigations to do and to arrive at the diagnosis. (Management not discussed). Peripheral smear findings with pictures are included.
Hemolytic anemia occurs when the bone marrow is unable to increase production to make up for the premature destruction of red blood cells and the abnormal breakdown of red blood cells either in the blood vessels (intravascular hemolysis) or elsewhere in the body (extravascular). It has numerous possible causes, ranging from relatively harmless to life-threatening. The general classification of hemolytic anemia is either inherited or acquired. Treatment depends on the cause and nature of the breakdown.Symptoms of hemolytic anemia are similar to other forms of anemia (fatigue and shortness of breath), but in addition the breakdown of red cells leads to jaundice and increases the risk of particular long-term complications such as gallstones and pulmonary hypertension.
Hemolytic anemia occurs when the bone marrow is unable to increase production to make up for the premature destruction of red blood cells and the abnormal breakdown of red blood cells either in the blood vessels (intravascular hemolysis) or elsewhere in the body (extravascular). It has numerous possible causes, ranging from relatively harmless to life-threatening. The general classification of hemolytic anemia is either inherited or acquired. Treatment depends on the cause and nature of the breakdown.Symptoms of hemolytic anemia are similar to other forms of anemia (fatigue and shortness of breath), but in addition the breakdown of red cells leads to jaundice and increases the risk of particular long-term complications such as gallstones and pulmonary hypertension.
Iron deficiency Anaemia is the most common nutritional deficiency in the world. This presentation to learn about Iron deficiency Anaemia. Here I discuss causes, clinical features, lab diagnosis and treatment of Iron deficiency Anaemia. I think it will help those who want to know about IDA.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
4. IRON DEFICIENCY ANEMIA
Introduction
Iron metabolism:
Daily 10-30mg iron ingested, 5-10% absorbed
to balance precisely the amount lost (1mg)
under physiologic condition
Amount absorbed can increases up to five
fold if body iron store are depleted or
erythropoiesis is accelerated.
Absorbed as hem and non hem iron in the
duodenum and proximal jejunum
5. IRON DEFICIENCY ANEMIA
Definition: - Iron deficiency anemia occurs
when body iron stores become inadequate for
the needs of normal RBC production
On a worldwide basis, iron deficiency is
among the most frequent causes of anemia.
6. IRON DEFICENCY - STAGES
• Prelatent
– reduction in iron stores without reduced serum iron levels
• Hb (N), MCV (N), iron absorption ( ), transferin
saturation (N), serum ferritin ( ), marrow iron ( )
• Latent
– iron stores are exhausted, but the blood hemoglobin level remains
normal
• Hb (N), MCV (N), TIBC ( ), serum ferritin ( ), transferrin
saturation ( ), marrow iron (absent)
• Iron deficiency anemia
– blood hemoglobin concentration falls below the lower limit of normal
• Hb ( ), MCV ( ), TIBC ( ), serum ferritin ( ), transferrin
saturation ( ), marrow iron (absent)
8. Etiologies of Iron deficnecy Anemia
• Chronic blood loss
• Increased demands
• Mal absorption of iron
• Poor diet
9. Management
History and physical examination is sufficient
to exclude serious disease (e.g pregnant or
lactating women, adolescents)
- treat ANEMIA
History and/or physical examination is
insufficient (e.g old men, postmenopausal
women)
10. Rx
• ORAL
– 200 mg of iron daily 1 hour before meal (e.g. 100
mg twice daily)
– How long?
• 14 days + (Hg required level – Hg current level) x 4
– half of the dose - 6 – 9 months to restore iron
reserve
– Absorption
• is enhanced: vit C, meat, orange juice, fish , Stomach
acidity
• is inhibited: cereals, tea, milk
11. PARENTERAL IRON SUBSTITUTION
– Bad oral iron tolerance (nausea, diarrhoea)
– Negative oral iron absorption test
– Necessity of quick management (CHD, CHF)
– 50 - 100 mg daily
– I.v only in hospital (risk of anaphilactic shock)
– I.m in outpatient department
– iron to be injected (mg) = (15 - Hb/g%/) x body
weight (kg) x 3
12. Inadequate response may imply
Continuing hemorrhage
non compliance to therapy
Wrong diagnosis
Mixed deficiency – associated folate or vit.B12
deficiency
Another cause for anemia e.g. malignancy,
inflammation
Malabsorption – rare cause
Use of slow release preparations
13. Anemia of chronic disease
• ACD is a common type of anemia that occurs
in patients with infectious, inflammatory, or
neoplastic diseases that persist for more than
1 or 2 months.
• It does not include anemias caused by
marrow replacement, blood loss, hemolysis,
renal insufficiency, hepatic disease, or
endocrinopathy, even when these disirders
are chronic.
14. Etiologies
Chronic inflammatory diseases
- Infections e.g. pulmonary abscess, TB,
Osteomyelitis, pneumonia, bacterial
endocarditis
- Non infectious, e.g. Rheumatoid arthritis, SLE
and other connective tissue
diseases,sarcoidosis, Crohn’s disease
Malignant diseases
E.g. carcinoma, lymphoma, sarcoma
15. Characteristic features are:
NCNC or mildly hypochromic indices and red
cell morphology
Mild and non progressive anemia (Hgb rarely
< 9.0g/dl) : Severity being related to severity
of underlying disease
Both serum iron and TIBC are reduced
Serum ferritine is normal or raised and
Bone marrow storage iron is normal but
erythroblast iron is reduced
16. pathogenesis
• Shortened red cell life span, moderately 20-30%
(from 120 to 60-90 days)
• Relative bone marrow(erythropoiesis) failure
- Cytokines released from inflammatory cells (TNF- ,
IL-1, IFN- ) affects erythropoiesis by inhibiting the
growth of erythroid progenitors
- Serum erythropoietin levels in patiens with ACD are
normal when compared to healthy subjects but much
lower than levels in non-ACD anemic patients
17. CON
• ABNORMAL IRON METABOLISM
• Activation of the reticuloendothelial system with
increased iron retention and storage within it
• Impaired release of iron from macrophages to
circulating transferrin (impaired reutilization of
iron)
• Reduced concentration of transferrin
(decreased production, increase sequestration in
the spleen and in the foci of inflammation,
increase loss)
18. Treatment of Anemia
Correction of underlying disease
Erythropoietin (40-80 % success rate)
Correction of reversible contributors (iron,
folate, cobalamine supplements if necessary)
19. MEGALOBLASTIC ANEMIAS
The megaloblastic anemias are caused by a
deficiency of vitamin B12 or folates,or by
related conditions that lead to impaired DNA
synthesis.
MCV>100fL
20. Etiologies
Vitamin B12 deficiency
Folate deficiency
Abnormalities of vitamin B12 or folate
metabolism,transcobalamine
deficiency,antifolate-drugs
Other defects of DNA synthesis: congenital
enzyme deficiency, alcohol, treatment with
hydroxyurea
21. B12: Cobalamin absorption
Initially bound to protein in diet,
liberated by acid and pepsin,
then binds to R factors in saliva
and gastric acids
Freed from R factors by
pancreatic proteases them binds
to Intrinsic Factor secreted by
gastric parietal cells
Absorbed together (Cbl + IF) in
ileum
Released from IF in ileal cell then
exocytosed bound to trans-Cbl II
Cbl bound to transcobalamin II
binds to cell surface receptors
and is endocytosed
22. Causes of Vit. B12 deficiency
Nutritional: especially in vegans
Malabsorption
Gastric causes
-pernicious anemia
-Congenital lack or abnormality of intrinsic factor
-Total or partial gastrectomy
Intestinal causes
-Ileal resection and Crohn’s disease
-Congenital selective malabsorption
23. Pernicious Anemia
Autoantibody to Intrinsic Factor detectable in <70%
– Highly specific, but insensitive
– 2 types of anti-IF antibody
• Blocks attachment of Cbl to IF
• Blocks attachment of Cbl-IF complex to ileal receptors
Chronic atrophic gastritis
– Autoantibody against parietal cells (H-K-ATPase) though
pathology indicates destruction by CD4+ T cells
– Increased risk of gastric cancer (carcinoid and intestinal-
type)
24. B12 Deficiency Symptoms
• Atrophic glossitis (shiny tongue)
• Shuffling broad gait
• Anemia and related sx
• Vaginal atrophy
• Malabsorption
• Jaundice
• Personality changes
• Hyperhomocysteinemia
• Neurologic symptoms (next slide)
• Copper deficiency can cause similar neurologic
symptoms
25. B12 Symptoms: Neurologic
Paresthesias
Memory loss
Numbness
Weakness
Loss of dexterity due to loss
of vibration and position
sense
Symmetric neuropathy
legs>arms
Severe weakness, spasticity,
clonus, paraplegia and
incontinence
Subacute combined
degeneration of the dorsal
(posterior) and lateral spinal
columns
Due to a defect in myelination
NOT ALL PATIENTS WITH B12
DEFICIENCY RELATED NEUROLOGIC
ABNORMALITIES ARE ANEMIA OR
MACROCYTOSIS
26. B12 Lab findings
Macroovalocytic anemia
with elevated serum bili and
LDH
Increased red cell
breakdown due to
ineffective
hematopoiesis
Retic, WBC & platelets
normal to low
Hypersegmented neurophils
Also occur in renal
failure, fe deficiency,
inherited
27. Bone Marrow
Hypercellular marrow
Megaloblastic erythroid
hyperplasia
Giant metamyelocytes
Due to slowing of DNA synthesis
and delayed nuclear maturation
Methionine deficiency may play a
central role
28. Shilling Test
1. PART 1: Oral labeled B12 and
IM unlabeled B12 at the
same time to saturate tissue
stores
2. 24h urine to assess absorption
>5% normal
<5% impaired
3. PART 2: Repeat w/oral IF
if now normal =PA
if abnormal = malabsorption
4. Can continue with antibiotics
to look for bacterial
overgrowth, pancreatic
enzymes for exocrine
insufficiency
Part 1 test result Part 2 test result Diagnosis
Normal -
Normal or vitamin
B12 deficiency
Low Normal Pernicious anemia
Low Low Malabsorption
29. B12 Deficiency: Treatment
IM B12 1000mcg daily x 1 wk
– then 1000mcg weekly x 1 month
– Then 1000mcg monthly for life for PA
Oral high dose 1-2 mg daily
– As effective but less reliable than IM
– Currently only recommended after
full parenteral repletion
Sublingual, nasal spray and gel formulations
available
30. Folate
• Animal products (liver), yeast and leafy
vegetables
• Normal requirement 400mcg/day
• Pregnancy/Lactation: 500-800mcg/day
• Increased requirement in hemolytic anemia
and exfoliateive skin disease
• Body stores: 5-10mg
32. Folate deficiency symptoms
• The symptoms of severe folate deficiency are
similar to those in severe vitamin B12
deficiency.
• However, there are no neurological signs and
symptoms.
33. Folate Deficiency Treatment
• Oral folate 1mg daily for 4 months or until
hematologic recovery
• Rule out B12 deficiency prior to treament as
folic acid will not prevent progression of
neurologic manifestations of B12 deficiency
• Repeat testing for B12 deficiency may be
reasonable for those on long-term folic acid
therapy if hematologic (macrocytosis or
↑LDH) or neurologic sx persist
34. SICKLE CELL ANEMIA
A serious condition in which red blood
cells can become sickle-shaped
Normal red blood cells are smooth
and round. They move easily through
blood vessels to carry oxygen to all
parts of the body.
Sickle-shaped cells don’t move easily
through blood. They’re stiff and sticky
and tend to form clumps and get
stuck in blood vessels.
The clumps of sickle cell block blood
flow in the blood vessels that lead to
the limbs and organs. Blocked blood
vessel can cause pain, serious
infection, and organ damage.
36. Mechanism
• Underlying mechanism of disease: sickle cell
anemia is a Glu->Val substitution in the sixth
amino acid of the β-globin gene
37. Sickle Cell Anemia vs. Sickle Cell Trait
• People who have sickle cell anemia are born with
it; means inherited, lifelong condition.
• They inherit two copies of sickle cell gene, one
from each parent.
• Sickle cell trait is different from sickle cell anemia.
People with sickle cell trait don’t have the
condition, but they have one of the genes that
cause the condition.
• People with sickle cell anemia and sickle cell trait
can pass the gene on when they have children
39. Why Anemia?
• In sickle cell anemia, a lower-than-normal
number of red blood cells occurs because
sickle cells don’t last very long.
• Sickle cells die faster than normal red blood
cells, usually after only about 10 to 20 days.
• The bone marrow can’t make new red blood
cells fast enough to replace the dying ones.
The result is anemia.
41. Complication of Sickle Cell Anemia
• Splenic Crisis
• Infections
• Acute Chest Syndrome
• Delayed growth and
puberty in children
• Stroke
• Eye problem
• Priapism
•Gallstone
•Ulcers on the
legs
•Pulmonary
Arterial
•Hypertension
• Organ Failure
42. Treatments
Effective treatments are available to help relieve the
symptoms and complications of sickle cell anemia, but
in most cases there’s no cure.
The goal is to relieve the pain; prevent infections, eye
damage, strokes and control complications if they
occur.
Pain medicine: acetaminophen, nonsteroidal anti-
inflammatory drugs (NSAIDs), and narcotics such as
meperidine, morphine, oxycodone, and etc.
Heating pads
Hydroxyurea, Folic Acid
Blood Transfusions
43. Prevention
Identify what can trigger the “Crisis” such as
stress, avoid extremes of heat and cold weather
Maintain healthy lifestyle habits
Eating healthy
Avoid dehydration
Exercise regularly
Get enough sleep and rest
Avoid alcohol and don’t smoke
Regular medical checkups and treatment are
important
44. Sideroblastic anemia
It is a refractory microcytic hypochromic anaemia (peripheral
blood) characterized by the presence of sidroblasts in the bone
marrow.
Sidroblasts are:
Erythroblasts inside which iron accumulate into the
mitochondria of erythroblasts owing to disordered haeme
synthesis .
A ring of iron granules is formed around the nucleus.
45. Classification
• Hereditary (sex linked recessive trait)
• Acquired
• Primary :Myelodysplasia
• Secondary :
-Malignant diseases of the marrow
-Drugs e.g. cycloserin alcohol, lead
-Others: hemolytic anemia, megaloblastic
anemia, malabsorption
46. Diagnostic
• The bone marrow biopsy is
diagnostic: it reveals
erythroid dysplasia and
hyperplasia.
• Ringed sideroblasts
comprise more than 20% of
the erythroid series
47. Thalassemia
• Inherited hematologic disorders caused by
defects in the synthesis of one or more of the
haemoglobin chains
• Two type
- alpha Thalassemia
- beta Thalassemia
48. CON
• Alpha thalassemia is the result of deficient or
absent synthesis of alpha globin chains,
leading to excess beta globin chains.
• Beta thalassemia is the result of deficient or
absent synthesis of beta globin chains, leading
to excess alpha chains
49. CON
• It cause haemolysis and defective
erythropoiesis
• Silent carriers of alpha thalassemia and
persons with alpha or beta thalassemia trait
are asymptomatic and require no treatment
50. CON
• Alpha Thalassemia intermedia, or hemoglobin
H disease, causes hemolytic anemia.
• Alpha Thalassemia major with hemoglobin
Bart's usually results in fatal hydrops fetalis.
• Beta Thalassemia major causes hemolytic
anemia, poor growth, and skeletal
abnormalities during infancy
51. Diagnosis
• A very low MCV should lead to a suspicion
particularly if <70 MCV in any patient
• Ferritin level become normal
• RDW normal
• Mentzer index = MCV/RBC count become <13
52. Treatment
• Treatment include -life long transfution
-Bone marrow transplant
-Preconception councelling
• Prognosis -Persons with beta thalassemia
major often die from cardiac complications of
iron overload by 30 years of age.
53. Hemolytic anemia
Anemia due to shortened survival of
circulating RBCs (Normal: 110-120 days)
– Hemolysis <100 days
With intact bone marrow:
• Anemia Compensatory increase in Epo
secretion Enhances RBC production
(reticulocytosis) Reduces degree of anemia
• This is most commonly seen with hemolytic
anemia, but not specific to hemolysis (can also be
seen with acute blood loss)
54. Causes of Hemolysis - Intrinsic
• Generally, a hereditary disorder
• Remember, the mature RBC has lost its nucleus,
mitochondria, and RNA, leaving Hgb, RBC
membrane
• Intrinsic hemolysis is caused by defects in Hgb,
RBC membrane or metabolic factors needed to
generate ATP
• Examples
• Thalassemia (defect in alpha or beta globin chains)
• Spherocytosis (missing RBC membrane proteins)
• G6PD deficiency (abnormality in reducing power (NADPH))
55. Causes of Hemolysis - Extrinsic
• Acquired disorder
• Causes include:
• Ab directed against RBC membrane components
-AIHA, delayed transfusion reaction
• Stasis/trapping/destruction in spleen (hypersplenism)
• Trauma
-Prosthetic heart valve
• Exposure to compounds with oxidant potential
-Sulfonamide in those with G6PD
• Destruction of RBC by pathogens
-Malaria, babesiosis
56. Site of Hemolysis
• Dependant on the severity and type of cell
alteration (alteration in RBC membrane)
• Severe damage immediate lysis in the
circulation (INTRAVASCULAR)
• Less severe damage cell destruction is via
the monocyte-macrophage system in the liver,
spleen, BM, lymph node (EXTRAVASCULAR
57. Intravascular Hemolysis
• Intravascular hemolysis Release of Hgb into
the plasma
• Free Hgb binds to haptoglobin Hgb-
haptoglobin complex is taken up by liver
Decrease in plasma haptoglobin
• Free Hgb breaks down to alpha-beta dimers
filtered by glomerulus Hemoglobinuria
59. Extravascular Hemolysis
• Damaged RBCs are destroyed by liver (receives a larger
portion of the cardiac output) and spleen
• Spleen contains cords of Billroth, which end blindly (unlike
other vascular channels in body)
• RBCs must deform to pass through 2-3 micron slits in the wall
of the cords in order to get back into circulation
• RBCs unable to pass are phagocytosed by the monocyte-
macrophage system
– Degraded into biliverdin, iron, carbon monoxide
60. Features of Hemolysis
Rapid fall in Hgb
Increased LDH, decreased Haptoglobin
Jaundice (elevated indirect bilirubin)
Splenomegaly
H/o pigmented gallstones
Abnormally shaped RBCs
Reticulocytosis
62. con
• RBCs with inclusions
• Teardrop RBCs
• Red Cell “ghosts”
– Hemolyzed RBCs that reform, but have lost all
internal components, leaving only the membrane
– Indicates Intravascular Hemolysis
63. Labs
LDH: elevated
Indirect bilirubin: elevated (due to catabolism of Hgb)
Haptoglobin: decreased
Binds to Hgb and taken up by liver
In a series of reports:
Elevated LDH, low Haptoglobin was 90% specific
Normal LDH, Haptoglobin >25 was 92% sensitive for ruling out
hemolysis
Reticulocyte Count: elevated
Normal is 0.5-1.5%
Anemia leads to increase Epo production leading to a
reticulocytosis (4-5% increase above baseline)
Positive Direct Antiglobulin Test (Coombs)
64. Acquired hemolytic anemia
• They are classified as
-Immune hemolytic anemia
-Traumatic anemia
-Others like infectious agents,chemicals
,toxins,paraxismal nocturnal hemoglobin
uria
65. Immune Hemolytic Anemia
• IgG and/or IgM bind to RBC surface Ag and
initiate RBC destruction via
– Complement system
– Reticuloendothelial system
• AutoImmune Hemolytic Anemia
– Production of Ab directed against self RBCs
67. Warm AIHA
48-79% of AIHA
Incidence increased at 40yrs
2:1 Female to Male ratio
No racial predilection
Idiopathic vs Secondary Causes
CLL, Hodgkins, non-Hodgkins,
Autoimmune, non-lymphoid neoplasms, immunodeficiency, viral
illnesses
Typically present with anemic signs and symptoms
These symptoms may precede and underlying illness by
months to years
68. Warm AIHA - Labs
• Elevated MCV (reflecting reticulocytosis)
• Mild leukocytosis with neutrophilia
• Blood smear:
– Polychromasia, macrocytosis, spherocytes, nucleated RBCs
• Elevated LDH and indirect bilirubin
• Haptoglobin typically low
– Because it is an acute phase reactant, it can also be normal
or elevated in mild disease
69. Warm AIHA – DAT (direct Coombs)
Detects Ab on the RBC surface
Pt’s RBCs are washed then reacted with
monoclonal Ab against various Ig (IgG) and C3
Warm autoantibodies react at warmer
temperatures (~37° C)
95% of Warm AIHA will have a positive DAT
Negative tests due to:
IgG quantity too low for detectable threshold
IgA autoantibodies
IgM autoantibodies
70. Warm AIHA - Treatment
Folic Acid
Further treatment depends on severity
Steroids – 1mg/kg/day
Splenectomy
Removes source of extravascular hemolysis
Removes a site of Ab production
Cytotoxic drugs
Cyclosporine
Azathiaprine
71. Cold Agglutinin Syndrome (CAS)
• 16-32% of AIHA
• after binding to RBCs, IgM activates complement
cascade - C3b binds, phagocytosis by hepatic
macrophages (rather than splenic RES cells)
• Most commonly in the 7th decade/60 ths
• Idiopathic or secondary (most commonly
infection or lymphoproliferative disorders)
• RBC clumping (leads to artifactual elevation in
MCV and decreased RBC count)
72. CAS - Treatment
• Avoidance of cold exposure
– Move to a warmer climate
• Immunosuppression (cyclophosphamide)
• Plasmapheresis can temporarily help
• Compared to warm AIHI. . .
– Steroids are not beneficial
– Splenectomy is not beneficial
• Extravascular hemolysis typically occurs in liver
74. Non immune Hemolytic anemia
• Fragmentation Hemolysis (Microangiopathy) –
result of mechanical shearing of RBCs from
damaged microvasculature, cardiac
abnormalities, AV shunts, turbulent flow, drugs
(cyclosporine, cocaine)
• Hypersplenism – functionally hyperactive spleen
too much sequestration of all blood cells
• Infection – can be several mechanisms of
hemolysis (direct attack, hypersplenism
induction, immune, toxin release, altered RBC
surface)
• Burn ,liver disease
75. Lead poisoning
• Inhibits both hem and globin synthesis
• Interferes with breakdown of RNA by inhibiting the
enzyme pyrimidine- nucleotidase ⇒ accumulation of
denatured RNA in red cells giving rise to Basophilic
stippling.
• Hypo chromic/Hemolytic anemia with bone marrow
ring sideroblasts
• Free erythrocyte protoporphyrin is raised
Management:
• Pyridoxine, folic acid therapy : may bring some
response
• Repeated transfusion is ultimate choice